180 related articles for article (PubMed ID: 37215991)
21. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells.
Mansouri A; Ridgway LD; Korapati AL; Zhang Q; Tian L; Wang Y; Siddik ZH; Mills GB; Claret FX
J Biol Chem; 2003 May; 278(21):19245-56. PubMed ID: 12637505
[TBL] [Abstract][Full Text] [Related]
22. Enzyme kinetics and interaction studies for human JNK1β1 and substrates activating transcription factor 2 (ATF2) and c-Jun N-terminal kinase (c-Jun).
Figuera-Losada M; LoGrasso PV
J Biol Chem; 2012 Apr; 287(16):13291-302. PubMed ID: 22351776
[TBL] [Abstract][Full Text] [Related]
23. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
24. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
[TBL] [Abstract][Full Text] [Related]
25. Late activation of stress-activated protein kinases/c-Jun N-terminal kinases triggered by cisplatin-induced DNA damage in repair-defective cells.
Helbig L; Damrot J; Hülsenbeck J; Köberle B; Brozovic A; Osmak M; Fiket Z; Kaina B; Fritz G
J Biol Chem; 2011 Apr; 286(15):12991-3001. PubMed ID: 21324906
[TBL] [Abstract][Full Text] [Related]
26. miR-223/Hsp70/JNK/JUN/miR-223 feedback loop modulates the chemoresistance of osteosarcoma to cisplatin.
Tang Q; Yuan Q; Li H; Wang W; Xie G; Zhu K; Li D
Biochem Biophys Res Commun; 2018 Mar; 497(3):827-834. PubMed ID: 29432736
[TBL] [Abstract][Full Text] [Related]
27. Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines.
Sau A; Filomeni G; Pezzola S; D'Aguanno S; Tregno FP; Urbani A; Serra M; Pasello M; Picci P; Federici G; Caccuri AM
Mol Biosyst; 2012 Apr; 8(4):994-1006. PubMed ID: 22068640
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line.
Hayakawa J; Ohmichi M; Kurachi H; Ikegami H; Kimura A; Matsuoka T; Jikihara H; Mercola D; Murata Y
J Biol Chem; 1999 Oct; 274(44):31648-54. PubMed ID: 10531373
[TBL] [Abstract][Full Text] [Related]
29. Positive Feedback Loop of OCT4 and c-JUN Expedites Cancer Stemness in Liver Cancer.
Kuo KK; Lee KT; Chen KK; Yang YH; Lin YC; Tsai MH; Wuputra K; Lee YL; Ku CC; Miyoshi H; Nakamura Y; Saito S; Wu CC; Chai CY; Eckner R; Steve Lin CL; Wang SS; Wu DC; Lin CS; Yokoyama KK
Stem Cells; 2016 Nov; 34(11):2613-2624. PubMed ID: 27341307
[TBL] [Abstract][Full Text] [Related]
30. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
31. Lack of c-Jun activity increases survival to cisplatin.
Sánchez-Pérez I; Perona R
FEBS Lett; 1999 Jun; 453(1-2):151-8. PubMed ID: 10403393
[TBL] [Abstract][Full Text] [Related]
32. miR-23a promotes cisplatin chemoresistance and protects against cisplatin-induced apoptosis in tongue squamous cell carcinoma cells through Twist.
Peng F; Zhang H; Du Y; Tan P
Oncol Rep; 2015 Feb; 33(2):942-50. PubMed ID: 25501015
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of chemotherapeutic agents induced-apoptosis associated with activation of c-Jun N-terminal kinase 1 and caspase 3 (CPP32) in bax-transfected gastric cancer cells.
Kim R; Ohi Y; Inoue H; Toge T
Anticancer Res; 2000; 20(1A):439-44. PubMed ID: 10769693
[TBL] [Abstract][Full Text] [Related]
34. d-Borneol enhances cisplatin sensitivity via p21/p27-mediated S-phase arrest and cell apoptosis in non-small cell lung cancer cells and a murine xenograft model.
Li J; Yuan J; Li Y; Wang J; Gong D; Xie Q; Ma R; Wang J; Ren M; Lu D; Xu Z
Cell Mol Biol Lett; 2022 Jul; 27(1):61. PubMed ID: 35883026
[TBL] [Abstract][Full Text] [Related]
35. Cancer-specific enhancement of cisplatin-induced cytotoxicity with triptolide through an interaction of inactivated glycogen synthase kinase-3beta with p53.
Matsui Y; Watanabe J; Ikegawa M; Kamoto T; Ogawa O; Nishiyama H
Oncogene; 2008 Jul; 27(33):4603-14. PubMed ID: 18391982
[TBL] [Abstract][Full Text] [Related]
36. The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy.
Chen J; Solomides C; Simpkins F; Simpkins H
Cancer Chemother Pharmacol; 2017 Feb; 79(2):369-380. PubMed ID: 28120035
[TBL] [Abstract][Full Text] [Related]
37. HtrA1 Down-regulation Induces Cisplatin Resistance in Colon Cancer by Increasing XIAP and Activating PI3K/Akt Pathway.
Xiong Z; Fu Z; Shi J; Jiang X; Wan H
Ann Clin Lab Sci; 2017 May; 47(3):264-270. PubMed ID: 28667026
[TBL] [Abstract][Full Text] [Related]
38. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2.
Chung LY; Tang SJ; Sun GH; Chou TY; Yeh TS; Yu SL; Sun KH
Clin Cancer Res; 2012 Aug; 18(15):4037-47. PubMed ID: 22696230
[TBL] [Abstract][Full Text] [Related]
39. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance.
Brozovic A; Osmak M
Cancer Lett; 2007 Jun; 251(1):1-16. PubMed ID: 17125914
[TBL] [Abstract][Full Text] [Related]
40. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
